Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 31

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 8
Chunk 31
---
 2,486 common shares, (ii) 9,238 common shares issuable upon exercise of options exercisable within sixty days of December 12, 2025 and (iii) 18,768 common shares issuable upon the conversion of restricted share units that have vested or will vest within sixty days of December 12, 2025.

			(12)

			Consists of (i) 612,156 common shares, (ii) 154,270 common shares issuable upon exercise of options exercisable within sixty days of December 12, 2025, (iii) 359,473 common shares issuable upon exercise of warrants exercisable within sixty days of December 12, 2025, (iv) 425,172 common shares issuable upon conversion of restricted share units that have vested or will vest within sixty days of December 12, 2025, and (v) 712,500 common shares issuable upon conversion of preferred shares within sixty days of December 12, 2025.

Shareholders Known by Us to Own 5% or More of Our Common Shares

			Name and Address of Beneficial Owner

			Number of Shares Beneficially Owned

			Percentage of Shares Beneficially Owned

			Velan Capital Management LLC(1)

			 848,647

			(1)

			 9.99

			% 

			Stonepine Capital Management, LLC(2)

			 781,250

			(2)

			 9.3

			% 

			Nantahala Capital Management, LLC (3)

			 855,584

			(3)

			 9.99

			% 

			Rubric Capital Management LP(4)

			 848,647

			(4)

			 9.99

			% 

			(1)

			Consists of (A)(i) 421,875 common shares, (ii) 63,492 common shares issuable upon exercise of warrants within sixty days of December 12, 2025 and (iii) 97,655 common shares issuable upon conversion of Series B-1 Preferred Shares within sixty days of December 12, 2025 that are beneficially owned and deemed outstanding with respect to Velan Capital Master Fund LP (“Velan Master”), (B) 15,625 common shares held by Velan Horizon Fund LP (“Velan Horizon